Search results
Results from the WOW.Com Content Network
Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to ...
Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社, Ōtsuka Seiyaku Kabushiki-gaisha) (TYO: 4578), abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964.
Citi analysts forecast 19% earnings growth for the healthcare sector in 2025, up from 4% this year. The analysts point to the stocks' right-sized valuations and a potential improvement in ...
TOKYO (Reuters) -Japan's Otsuka Pharmaceutical said on Thursday it agreed to pay more than $1 billion to acquire Jnana Therapeutics as it looks to expand its drug pipeline and research base in the ...
In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. [10] Following the acquisition, SuperGen, Inc. changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. [11] The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
NEW YORK (AP) — U.S. stocks rose Friday to turn what would have been one of the market’s worst weeks of the year into just a pretty bad one. The S&P 500 rallied 1.1% for its best day in six ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.